Zobrazeno 1 - 8
of 8
pro vyhledávání: '"David Flyer"'
Autor:
Jing-Hui Tian, Michael J. Massare, Vadim A. Ivanov, Robert C. Welliver, Larry Ellingsworth, Gale Smith, Hanxin Lu, James F. Papin, Mimi Guebre-Xabier, David Flyer, Greg Glenn, Alisha Preno
Publikováno v:
Vaccine. 38(5)
Globally, human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infection in infants and young children. There are no licensed vaccines despite the high worldwide disease burden. RSV fusion (F) glycoprotein vaccine is t
Autor:
Xiaorui Chen, Jing-Hui Tian, Gale Smith, Jianpeng Ma, Ye Liu, Zhao Wang, Hanxin Lu, Fengyun Ni, Gregory M. Glenn, David Flyer, Nita Patel, Qinghua Wang, Qingqing Xie, Michael J. Massare, Larry Ellingsworth
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0210749 (2019)
PLoS ONE
PLoS ONE
Globally, human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in newborns, young children, and the elderly for which there is no vaccine. The RSV fusion (F) glycoprotein is a major target for vaccine devel
Autor:
Hannah M. Creager, Michael J. Massare, Ye V. Liu, Min Z. Levine, Melissa B. Pearce, David Flyer, Gregory M. Glenn, Gale Smith, Peter Pushko, Yaohui Bai, Jessica A. Belser, Taronna R. Maines, Terrence M. Tumpey, Xiangjie Sun
Publikováno v:
Virology. 509
Avian influenza A (H5N1) viruses represent a growing threat for an influenza pandemic. The presence of widespread avian influenza virus infections further emphasizes the need for vaccine strategies for control of pre-pandemic H5N1 and other avian inf
Autor:
Ye V. Liu, Thiagarajan Venkataraman, Gregory M. Glenn, Matthew B. Frieman, Gale Smith, Christopher M. Coleman, David Flyer
Publikováno v:
Vaccine
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike
Autor:
David Flyer, Matthew B. Frieman, Gale Smith, Haiyan Mu, Gregory M. Glenn, Michael J. Massare, Ye V. Liu, Justin K. Taylor, Christopher M. Coleman
Publikováno v:
Vaccine
Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a
Autor:
Eloi Kpamegan, Louis Fries, Denise Courbron, Yingyun Wu, Gale Smith, Ziping Wei, Ramadevi Raghunandan, Gregory M. Glenn, David Flyer, Ye Liu
Publikováno v:
Vaccine. 31(40)
The recent emergence of severe human illness caused by avian-origin influenza A(H7N9) viruses in China has precipitated a global effort to rapidly develop and test vaccine candidates. To date, non-A(H7N9) H7 subtype influenza vaccine candidates have
Autor:
Hanxin Lu, Bin Zhou, Gregory M. Glenn, Margret Nathan, Ye Liu, Sarathi Boddapati, Jingning Li, Yingyun Wu, Gale Smith, Michael J. Massare, Rama Raghunandan, David Flyer
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 11, p e50852 (2012)
PLoS ONE, Vol 7, Iss 11, p e50852 (2012)
Respiratory Syncytial Virus (RSV) is an important viral agent causing severe respiratory tract disease in infants and children as well as in the elderly and immunocompromised individuals. The lack of a safe and effective RSV vaccine represents a majo
Autor:
Hanxin Lu, Rama Raghunandan, Mimi Guebre Xabier, David Flyer, Louis Fries, Bin Zhou, Gregory M. Glenn, Michael J. Massare, Gale Smith
Publikováno v:
Vaccine
Highlights • RSV F nanoparticle vaccine induced palivizumab competing antibodies (PCA). • PCA is in excess of serum protective levels than IM injected palivizumab. • Live virus infection induces little or no PCA. • Passively administered RSV